ArticlePregnancy (Hoboken, N.J.)2026
Feasibility of implementing a standardized preeclampsia risk screening tool into the electronic medical record.
Article in Pregnancy (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Disparities in low-dose aspirin prescription among patients at risk for preeclampsia.Pregnancy (Hoboken, N.J.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Background: Despite the fact that low-dose aspirin (LDA) is the only effective intervention for preeclampsia risk reduction, not all those at increased risk of preeclampsia are recommended it. This study examines feasibility of implementing a preeclampsia risk screening tool into the electronic health record (EHR) to prompt LDA recommendation when appropriate and assesses whether there are differences in screening rates by race/ethnicity, language, or insurance payor. Methods: A standardized preeclampsia risk screening tool was launched in September 2022, which was intended to be used for all obstetrical patients to assess LDA eligibility. To assess feasibility of this tool, we conducted a retrospective cohort study of patients who delivered at an academic medical center from July 2023 to June 2024. The primary outcome of this was feasibility, defined as percentage of patients who delivered each month who had been screened using the tool. The secondary outcome was association between sociodemographic characteristics and screening. Chi-square and Student's Results: A total of 4556 patients met inclusion criteria, and 2521 (55.3%) were screened using the tool. Tool use increased from 46.2% in the first month to 67.4% in the last month of the study, with the odds of the tool being used increasing on average 7% per month over 1 year ( Conclusions: Preeclampsia risk screening increased substantially after implementing this standardized tool into the EHR which demonstrates its feasibility. We observed disparities in screening rates by race/ethnicity, language, and insurance payor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.